InVasc Therapeutics

About:

InVasc Therapeutics develops drug-based platforms for diabetes, atherosclerosis, hypertension, and cardiovascular diseases.

Website: http://www.invasc.net

Top Investors: Trois I Investments Industriels Internationaux

Description:

InVasc Therapeutics was founded in 2006 by three leading researchers at Emory University and Ohio State University. These three researchers began their fifteen-year research and clinical collaboration at Emory University. InVasc was formed to develop several platforms of drugs to combat cardiometabolic conditions such as diabetes, atherosclerosis, hypertension and cardiovascular diseases and their complications. In the spring of 2010, the Company transitioned from an early phase start up led by academic researchers to a development organization by adding two senior executives with more than 70 years of combined executive and product development experience in the pharmaceutical, medical device and biotechnology industry.

Total Funding Amount:

$3.1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Tucker, Georgia, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)invasctherapeutics.com

Founders:

Bobby V. Khan

Number of Employees:

1-10

Last Funding Date:

2010-10-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai